Randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of desmoteplase in acute ischemic stroke09/01/2009 - 12/31/2014 (PI)
Lundbeck, Inc.
A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab)10/21/2013 - 11/30/2014 (PI)
Pfizer, Inc.
Personnel Agreement for Research Services of Ethan Treglia01/01/2011 - 09/30/2012 (PI)
VA Boston Healthcare System
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic D05/01/2008 - 04/30/2012 (PI)
Schering-Plough Research Institute
SPS312/01/2009 - 01/31/2012 (Subcontract PI)
University of British Columbia NIH NINDS
PREDICT (Predicting hEmatoma growth anD outcome in Intracerebral hemorrhage using contrast bolus CT) study11/01/2009 - 10/30/2010 (PI)
University of Calgary
PRoFESS- Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel and Aspirin, With and Without Micardis09/01/2003 - 08/31/2007 (PI)
Boehringer Ingelheim Pharmaceuticals
DIAS 2: Desmoteplase (INN) In Acute Ischemic Stroke: Phase III05/17/2005 - 12/31/2006 (PI)
Forest Laboratories, Inc./Forest Research Institute
Management of Atherothrombosis with Clopidogrel in High Risk Patients with Recent Transient Ischemic of Ischemic Stroke09/01/2001 - 08/31/2003 (PI)
Parexel Sanofi Synthelabo
Epidemiologic Study of Acute Ischemic Stroke (ESIS)09/22/2000 - 07/31/2003 (PI)
Genentech, Inc.
Showing 10 of 12 results.
Show All Results
A Multicenter, Stratified, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients With Acute Ischemic Stroke Given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo
05/16/2001 - 05/31/2003 (PI)
Cato Research Ltd (on behalf of Yamanouchi USA)
A Phase III Multicenter, Double Blind, Parallel Group Placebo Controlled Study of the Effect of Riluzole 50 mg BID or 100 mg BID on the Progression of Parkinson’s Disease in Patients Treated with L-Dopa or Dopamine Agonist
08/13/1999 - 08/30/2002 (PI)
Rhone-Poulenc Rorer Pharmaceuticals Inc
New England Regional Coordinating Center for the NINDS Stroke Trials Network09/30/2013 - 05/31/2020 (Multi-PI)
PI:
Carlos S. Kase, MDThe General Hospital Corporation / MGH National Institute o
New England Regional Coordinating Center for the NINDS Stroke Trials Network09/30/2013 - 07/31/2018 (PI)
Mass General Hosp NIH-NINDS
MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis with Altephase in MRI-Selected P…11/19/2014 - 12/31/2015 (PI)
Mass General Hosp Genentech
Insulin Resistance Intervention After Stroke Trial (IRIS)09/15/2004 - 08/31/2015 (PI)
Yale University NIH-NINDS
Bumpus Project 402/01/2004 - 01/31/2014 (PI)
Bumpus Foundation
MR Rescue06/01/2007 - 04/30/2013 (PI)
Univ of California, Los Angeles NIH-NINDS
MA Coverdell Stroke Registry Project06/09/2005 - 06/30/2009 (PI)
DPH
A Randomized Trial of Unruptured Brain Arteriovenous (ARUBA)01/13/2006 - 07/31/2008 (PI)
Columbia University NIHU01 NS0514843-01
Bumpus Parkinson'S Project 102/01/2001 - 02/01/2006 (PI)
Bumpus Foundation
Bumpus Parkinson'S Project 202/01/2001 - 02/01/2005 (PI)
Bumpus Foundation
Showing 10 of 11 results.
Show All Results
Clomethiazole Class-1 Stroke
07/01/1999 - 06/30/2001 (PI)
Parexel Intl Corp